A plasma protein marker panel for diagnosis of colorectal cancer
DKFZ Deutsches Krebsforschungszentrum
Sigmoidoscopy and colonoscopy, the current goldstandards for detection of CRC in the distal andtotal colorectum, respectively, are limited by several disadvantages, such as high costs, limited resources and poor compliance. So other costeffective and sensitive methods for the early detection of colorectal cancer are urgently needed and very important from the health economic standpoint. The invention offers a plasma protein biomarker set that can be used as a diagnostictool for diagnosis and stratification of colorectal cancer.
The Technology and Development Stage
Based on the prospective BliTz study from 2005–2012 including approximately 5500 participants a panel of 17 plasma proteins was identified by analysis of 35 CRC patients who were compared to a representative sample of 54 controls free of colorectal neoplasms. This set was further reduced to a core panel of 8 proteins without substantial loss of predictive power.
Applications and Commercial Opportunity
DKFZ is looking for a commercial partner for further development of the marker panel alone or in combination with other markers towards clinical application.
The investigators and inventors are: Chen Hongda and Hermann Brenner, both of DKFZ.
A priority patent application “Biomarker panel for diagnosing cancer” EP15161465.8 has been filed at the Europe Patent Office March 27, 2015. A subsequent international patent application was filed March 27, 2016 as PCT/EP2016/056314.
No further public information is currently available, but further information (speaking with the inventor) is available under a signed Confidential Disclosure Agreement (CDA).
For further information, including a CDA, please contact: